A liquid chromatography-electrospray-mass spectrometry technique for the screening and determination of five non-depolarizing neuromuscular blocking agents (NDBAs), atracurium and its product of degradation/metabolite laudanosine, rocuronium, pancuronium, vecuronium, and mivacurium has been developed using ambenonium as the internal standard (I.S.). Samples were acidified upon reception by adding 20 pL 0.SM H2SO4 to 500 pL of biofluid. Sample preparation consisted of simple blood purification and/or protein precipitation using 1 mL I.S. in acetonitrile.
[Abstract Introduction
A liquid chromatography-electrospray-mass spectrometry technique for the screening and determination of five non-depolarizing neuromuscular blocking agents (NDBAs), atracurium and its product of degradation/metabolite laudanosine, rocuronium, pancuronium, vecuronium, and mivacurium has been developed using ambenonium as the internal standard (I.S.). Samples were acidified upon reception by adding 20 pL 0.SM H2SO4 to 500 pL of biofluid. Sample preparation consisted of simple blood purification and/or protein precipitation using 1 mL I.S. in acetonitrile.
Chromatographic separation was carried out on an X-TERRA TM column along with a gradient of acetonitrile in 2ram ammonium formate (pH 3). Detection was carried out in the positive selected ion monitoring mode, targeting one quantitation ion and one confirmation ion per compound. The limit of quantitation was 2.5 pg/L for mivacurium and laudanosine, 5 pg/L for rocuronium and pancuronium and 10 pg/L for atracurium and vecuronium in serum (i.e., in the range of, or less than, therapeutic levels). The technique was found to be linear between the respective LOQs and 2000 pg/L, with correlation coefficients higher than 0.999 in all matrices. Intra-and interday precision and accuracy in serum fulfilled the international criteria. This method was employed for the investigation of a case of suicide by infusion of drugs. Laudanosine, the metabolite or degradation product of both atracurium and cisatracurium, and rocuronium were found in urine and whole blood, at supratherapeutic concentrations in the latter (rocuronium: 1.53 and 2.18 rag/L, laudanosine: 8.86 and 0.31 rag/L, respectively), and even therapeutic concentrations would have been lethal in the absence of respiratory assistance.
"Curare" is a mixture of different naturally occurring alkaloids found in various South American plants. Many of these substances have neuromuscular-blocking activity. These substances are all quaternary ammonium or bis-quaternary ammonium compounds, which means that they are poorly absorbed and generally quickly excreted. Two classes of neuromuscular-blocking agents co-exist with a different mechanism of action. The non-depolarizing blocking agents (NDBAs, e.g., atracurium, cisatracurium, mivacurium, pancuronium, rocuronium, vecuronium, etc.) act as competitive antagonists at the acetylcholine receptors of the muscular endplate, whereas the depolarizing blocking agents (DBA, e.g., suxamethonium) maintain depolarization at this endplate region. NDBAs are more often employed for clinical anesthesia than DBAs (1).
In the literature, different analytical methods have been proposed for the determination of neuromuscular-blocking drugs in blood. In most cases, liquid chromatography (LC) was chosen as the separation technique, and several detection modes were used. However, these methods (2-7) could determine only one or two of these drugs simultaneously. Other authors have used capillary gas chromatography and nitrogen-phosphorus detection for the quantitation of three NDBAs and their respective desacetyl metabolites (8) . A few papers have described the quantitation of NDBAs by liquid chromatography-mass spectrometry (LC-MS) (9,10) or LC-MS-MS (11), but here again only one or two molecules were studied. To the best of our knowledge, only one team has reported on the detection of several neuromuscular blocking agents by LC-MS (12), but no quantitative data were included.
Here we report a method for the sensitive and specific detection and quantitation by LC-MS of six of the most widely used NDBAs in biological fluids.
Materials and Methods

Chemicals and reagents
Atracurium besylate, mivacurium chloride, and cisatracurium besylate were obtained from Glaxo Wellcome (Marlyle-Roi, France); rocuronium bromide and vecuronium bromide were purchased from Riom Laboratories CERM (Puteaux, France); and pancuronium bromide was from Beaufour Ipsen Pharma (Paris, France). Laudanosine was obtained from Aldrich (Steinheim, Germany) and ambenonium, used as the internal standard (I.S.), from Sanofi-Synthelabo (Paris, France). Highperformance liquid chromatography (HPLC)-grade acetonitrile was purchased from Carlo-Erba (Milan, Italy), high-purity formic acid and ammonium formate were from Sigma (St. Louis, MO), and sulfuric acid was from Prolabo (Paris, France). All reagents were of the highest available purity and used as received without further purification. Deionized water was prepared on a MilliQ laboratory plant (Millipore, Bedford, MA).
Standards and solutions
Stock solutions at I g/L were prepared by diluting each drug, as a pure powder, with methanol (for ambenonium, mivacurium, rocuronium, and laudanosine) or acetonitrile (for atracurium, vecuronium, and pancuronium) depending on their solubility and stability. These stock solutions were stored at -20~ in the dark, conditions under which they were stable for at least three months. Working solutions of the mixture of the six analytes at 20, 10, 2, 0.5, and 0.1 mg/L were freshly prepared by dilution with 0.625mM sulfuric acid. A working solution of the internal standard at 10mg/L was also freshly prepared by dilution of the methanolic stock solution with deionized water.
Sample preparation
Samples of serum, plasma, whole blood, urine, and gastric content or lavage from living donors or corpses were collected in glass tubes and acidified by adding 20 IJL of 0.5M sulfuric acid and vortex mixed for 30 s, ideally before preservation at -20~ until analysis. Under these conditions, it was previously reported that atracurium and laudanosine were stable at least for 30 days (13) .
To a ]5-mL round-bottomed glass tube equipped with a PTFE-lined screw-cap were added 500 IJL serum or other biofluids, 20 ]~L of a 10 mg/L methanolic solution of ambenonium (I.S.), and I mL acetonitrile; the tube was immediately vortex mixed. Protein precipitation was allowed to take place for 10 rain, then the sample was centrifuged for 5 min at 2000 xg. The supernatant was transferred to a conical-bottomed glass tube and evaporated, under a gentle stream of nitrogen, down to 100 or 150 1JL. A 3-1JL aliquot was injected into the chromatographic system.
HPLC conditions
The HPLC system consisted of a series 200 autosampler connected to two series 200 LC micropumps (Perkin-Elmer, Norwalk, CT), and an X-Terra MS C18, 3.5 IJm column (150 x l-ram i.d.) (Waters, Saint-Quentin-en-Yvelines, France). The mobile phase, delivered at a constant flow-rate of 50 IJL/min, was a gradient of two solvents: (A) 2mM ammonium formate (pH 3) and (B) acetonitrile/2mM ammonium formate (pH 3) (90:10, v/v). The gradient elution profile was as follows: 15% B for 2 rain, increased to 43% for 8 rain, and followed by 1 rain reequilibration at 15% B.
MS
A single quadrupole atmospheric pressure ionization MS, model API-100 Perkin Elmer-Sciex, (Concord, ON, Canada), equipped with an electrospray-type, Ionspray TM source was employed. Ultra-high purity nitrogen was used as the nebulization and curtain gas. Calibration of the mass analyzer was performed by infusion (5 lJL/min) of a commercial mixture of PPGs (Applied Biosystems, Saint Quentin-en-Yvelines, France), using a Harvard model 11 syringe pump (Harvard Scientific, South Natick, MA) and monitoring eight mass-to-charge ratios in the 55 to 2300 u mass range. For optimization of the ionization and transmission conditions of each NDBA, 1 mg/L solutions of the pure compounds, in mobile phase, were infused into the ion source at a flow rate of 40 IJL/min. During this experiment, a m/z 200 to 1600 range was monitored with a resolution of 0.1 u.
For the quantitative determination of the six compounds, two mass-to-charge ratios corresponding to the quantitation and confirmation ions were monitored for each drug with a dwell-time of 150 ms each. These ions are presented in Table I .
The other main parameter settings of the MS were as follows: ionspray voltage, 5800 V; orifice voltage optimized for each mass-to-charge ratio (Table I) ; and electron multiplier, 2800 V.
Validation procedure
The limit of detection and linearity range of the present method were studied for whole blood, urine, and gastric liquid and the method was fully validated using drug-free human serum, as follows: calibration curves were obtained by analyzing serum samples fortified at 0, 10, 50, 200, 500, and 1000 IJg/L of each drug. Extraction recovery was calculated by comparison of the peak-area ratios of the analytes added to blank serum samples and extracted as previously described with those of unextracted standards at the same concentration. This procedure was repeated six times at two different concentration levels (25 and 1000 IJg/L). Intra-assay and interassay accuracy and precision CV were evaluated from the results of six replicates at four different concentrations under both conditions. The concentrations studied were the limit of quantitation (LOQ) of each compound, two intermediate points through the linearity range and the highest concentration of the calibration curve. The sample preparation procedure used was rapid and simple. No imprecision that could have possibly been brought about by evaporation of the extract was noted because of the presence of the internal standard. Ambenonium was chosen as the internal standard because it is a bis-quaternary ammonium salt like most NBDAs, and it is not licensed for therapeutic use in Europe and thus may not interfere with NBDAs. However, ambenonium is used as a therapeutic agent in the United States for the treatment of myasthenia gravis, so it would be better to use another internal standard in the U.S. (though there are not so many bis-quaternary ammonium organic compounds).
Results
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The main difficulty of this method was the chromatographic separation of the compounds with sufficient resolution and with no widening of the chromatographic peaks. The selected ion chromatogram shown in Figure I presents the chromatographic separation obtained with the gradient elution profile finally chosen. No interferences due to the matrix were observed, preserving the signal4o-noise ratio (S/N) at low concentrations. The peak under the vecuronium chromatographic peak at 6.8 min corresponds to m/z 430.5 selected for pancuronium identification and cannot interfere with the quantitation of vecuronium.
The mass spectra of the different compounds were first acquired in the full-scan mode at two different ion-source fragmentation energies (OR = 20 V and 80 V), during the infusion experiments: the first condition resulted in the maximum abundance of the pseudo-molecular ion and the second gave mainly fragments. The spectra of atracurium at OR = 20 V and 80 V are presented in Figure 2 , as examples. Finally, after selection of convenient quantitation and confirmation ions, quantitation was performed in the selected ion monitoring mode with optimized OR voltage for each mass-to-charge ratio selected. In the mass spectra of atracurium or cisatracurium (Figure 2) , some ions such as m/z 256.4 were more abundant < 9~176 than those selected (Table I ), but they were not selected because they were not specific < 8% enough because of high background noise in < 7% < 11% the low mass range. Also, high masses such as < 10% m/z 1085.8 might appear to be good candi-< 8% dates as quantitation ions but correspond to the salt forms of the compounds (besylate), which virtually do not exist in vivo, which is the reason why they were not selected. Finally, it is interesting to note that the quantitation ion chosen for atracurium (m/z 464.8) corresponds
to half the mass of the bis-quaternary ammonium (929.5 u) because of the presence of two charges (z = 2). In Table I The correlation coefficient of this method in serum was more than 0.999 for all the NDBAs studied (seven replicates of a seven-point linear regression study). The LODs were 2.5 I~g/L for rocuronium, pancuronium, mivacurium, and laudanosine and 5 Bg/L for vecuronium and atracurium, as defined by S/N > 3. The LOQs, defined as the lowest calibration level for which the intraday inaccuracy and precision CV were less than 15%, were 2.5 IJg/L for rnivacurium and laudanosine, 5 IJg/L for rocuronium and pancuronium, and 10 IJg/L for atracurium and vecuronium. Inaccuracy and precision CV at all concentrations above the LOQ were less than 14% during the intraday and less than 11% during the interday study (Table II) , that is, well within the consensus requirements for a validated method (14) . Other biological fluids (whole blood, plasma, urine, and gastric content) were tested by preparing a calibration curve in the same way as for serum in order to check the linearity between the concentration and the mass spectrometer response (Table III) . No interferences due to the matrices were observed. The calibration study showed that the method was linear in all these matrices in the range of 10 IJg/L to 2000 pg/L. To the best of our knowledge, the present analytical method is the first allowing several NDBAs to be determined in the same run by MS. The LOD and LOQ are either similar to or less than the best values previously reported (Table IV) for all the drugs studied, allowing quantitation of six NDBAs at low therapeutic levels, which is important because of the very short elimination half-lives of these drugs.
However, this analytical method cannot differentiate atracurium from cisatracurium. These two drugs are isomers and are eluted at exactly the same retention time using the present technique, despite the various attempts to separate them. The nature and relative intensities of the fragment ions in their mass spectra were also identical, and could not be distinguished. Moreover, they have a very short half-life, are unstable in vitro, particularly at high pH, temperature, and in the light (13) , and require storage at +4~ in the dark. Under physiological conditions, atracurium and cisatracurium are very quickly hydrolyzed by Hoffmann's reaction to give laudanosine. Laudanosine is not an NDBA itself but an inactive degra- dation product/metabolite of atracurium or cisatracurium, indistinctly, which is the reason why it was included in the present method. This validated method was then applied to a forensic case of suspicious death.
Case History
An M.D. was found dead in his medical office with a drip connected to his left arm. He was known to be a depressive patient. Whole blood, urine, and a sample of the infused liquid were collected to determine the cause of death.
The present analytical method revealed the presence of rocuronium and laudanosine in all samples. Whole blood concentrations were 1.53 mg/L and 8.86 rag/L, respectively. The toxicological screening analyses also found alfentanyl, phenoperidine, and dextromoramide in the blood, urine, and infused liquid. These compounds are commonly administered with NDBAs during anesthesia. Additionally, paroxetine was found at a therapeutic concentration in blood, which may have been part of a treatment for depression.
The results are detailed in Table V and the main chromatograms presented in Figure 3 . Retention times seem to be different than those on the chromatogram of spiked serum, but the relative retention times are identical. This is due to modifications of the retention properties of the analytical column with repeated use.
In the present forensic case, the presence of laudanosine in all samples (Table V) indicates that the infused liquid contained either atracurium or cisatracurium. The parent compound had completely disappeared, probably because the deceased was found several hours after death, and the samples were brought to our lab several days later at room temperature. The hypothesis that extraction from the infusion liquid was poor can be rejected because there was no extraction and the infused liquid was only diluted with the mobile phase before analysis. Moreover, Tracrium TM in glucose solution is known to be stable for a maximum of 8 h, as indicated by the manufacturer.
Typically, during anesthesia, patients receive 0.1 mg/kg cisatracurium or 0.5 mg/kg atracurium as a bolus dose, followed by continuous infusion at 0.27 to 1.77 mg/kg/h for atracurium and 0.03 to 0.6 mg/kg/h, depending on the patient, adjusted to maintain 95-99% of total neuromuscular blockade. With such doses, respiratory assistance is necessary. Clinical studies (15, 16) have reported that the plasma concentration of iaudanosine was usually less than 0.5 mg/L. Moreover, if cisatracufium is used, the plasma concentrations of laudanosine are even lower. Another study (13) showed that during a 72-h infusion of atracurium at I mg/kg/h, laudanosine plasma concentration was always less than 1 rag/L, compared to 8.86 mg/L in whole blood in the present lethal case.
In the light of these pharmacokinetic data, it was concluded that the concentrations of laudanosine found in this forensic case corresponded to atracurium or cisatracurium doses that could have led to death by respiratory paralysis in the absence of any respiratory assistance. Another fatality (17) was previously reported where laudanosine concentrations measured in blood by gas chromatography-mass spectrometry were at least 10 times lower than those in the present case.
The therapeutic dose of rocuronium commonly administered is 0.6 mg/kg as a bolus injection, followed by continuous infusion at 0.15 mg/kg. With such doses, respiratory assistance is compulsory. One paper (18) reported plasma concentration during different phases of liver transplantation surgery. The maximum observed concentration was 1.76 mg/L during the infusion, compared to 1.53 mg/L in the present case. So, here again, rocuronium could have been responsible for the death of this physician on its own, in the absence of any respiratory assistance. The combination of these two NDBg strongly supports their involvement in this fatality.
In summary, the present validated analytical method is simple and rapid enough to be used routinely for the identification and quantitation of six NDBAs at therapeutic levels, in clinical and forensic cases. Further improvements will be to include the main depolarizing neuromuscular blocking agents (DBAs) in this method.
